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Abstract
Matrix metalloproteinases (MMPs) are a class of structurally related enzymes that function in the degradation of
extracellular matrix proteins that constitute the pericellular connective tissue and play an important role in both
normal and pathological tissue remodelling. Increased MMP activity is detected in a wide range of cancers and
seems correlated to their invasive and metastatic potential. MMPs thus seem an attractive target for both diagnostic
and therapeutic purposes.
Several synthetic matrix metalloproteinase inhibitors (MMPIs) are currently being developed. Preclinical studies
are promising as they suggest inhibition of several steps in the metastatic process. Marimastat is the first MMPI
to enter comparative phase III trials after early clinical trials established the safety profile. Clinical trials will need
to be specifically designed to optimally evaluate the therapeutic potential of this novel class of cytostatic drugs.
Safety studies should consider the markedly different toxicity profile and determine the range of biologically active
dosage, while efficacy studies should be performed in selected clinical settings with appropriate end-points. We
review the present achievements in preclinical and clinical studies with MMPIs, discuss specific considerations for
appropriate study design and reflect on the future prospects of this novel class of agents.
Introduction
Matrix metalloproteinases (MMPs) function in the
degradationof extracellular matrix proteins that consti-
tute connective tissue. They are one of the four major
classes of proteases that play a role in the evolution
of cancer. Proteases in general play a role in many
diseases. The activity of most extracellular proteases
is controlled by specific naturally occurring inhibitors.
The importance of these inhibitors can be illustrat-
ed by the identification that their deficiency is relat-
ed to specific disease or disorders. Deficiency of for
instance antithrombine III relates to thrombosis, and
of a-antitrypsine to emphysema.
Proteases
Extracellular proteases are essential for tumor cells to
be able to penetrate the basement membrane. Prote-
olytic degradation of the extracellular matrix (ECM) is
also necessary when invasive tumor cells penetrate tis-
sues, gain acces to blood vessels, exit blood vessels and
colonise distant sites (metastasis). In addition, angio-
genesis (a neovascularization process crucial to sustain
tumor growth) involves activity proteolytic degrada-
tion of the ECM by invasive endothelial cells [1]. The
four classes of endopeptidases that play a role in these
processes are serine, cysteine, aspartyl and metallo-
proteinases [2]. Of the serine peptidases, urokinase
type plasminogen activator (uPA) and tissue type plas-
minogin activator (tPA) known to be produced by many
tumor cells [3, 4], generate plasmin from plasminogen.
Plasmin, in turn, is a know activator of several MMPs.
These are a family of structurally related enzymes that
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Table 1. Common features of MMPs
1. Produced in an inactive form
2. Two Zn2+ atoms, including one at the active site
3. Two CA2+ ions, essential for enzyme-stability
4. Primary structure typically contains two highly
conserved regions, 1 each in the N-terminal propetide
domain and in the catalytic domain
5. Inhibited by specific inhibitors known as tissue
inhibitors of metalloproteinases (TIMP)
contain a zinc atom at their active site (Table 1). As
early as in 1962, interstitial collagenases, responsible
for the resorption of tadpole tails [5], was the first
MMP to be described and purified. MMPs are secreted
as latent pro-enzymes and are activated by proteolyt-
ic removal of an amino-terminal domain [6]. MMPs
can be classified on the basis of sequence homology
and substrate specificity into four groups (Table 1).
The first group consists of three collagenases: inter-
stitial collagenase, neutrophil (PMN) collagenase, and
collagenase-3 which specifically degrade type I, II, and
III fibrillar collagens [7–9]. The second group consists
of the 72 kDa and 92 kDa gelatinases, also referred to
as type IV collagenases [10, 11], and metalloelastase.
The substrate specificity of the gelatinases is broad-
er than that of the collagenases. Both gelatinases will
degrade the type IV and V non-fibrillar collagens of
basal lamina, and have also been reported to degrade
type VII collagen, fibronectin [10], type X short chain
collagen [12] and elastin [13]. The latter is the sub-
strate for metalloelastase. The third group of MMPs
consists of two closely related enzymes, stromelysin-1
and stromelysin-2 [14, 15] and a more distantly relat-
ed enzyme, matrilysin (PUMP) [16]. They degrade a
wide variety of proteoglycans, fibronectin, laminin, as
well as type IV collagen [14] and type X collagen [17].
Stromelysin-3 [18] despite its name, does not neatly fit
into this group [19]. Although mRNA in situ hybridi-
sation studies suggest that stromelysin-3 is important
in malignant disease the proteolytic function of the
native protein has yet to be described. Recent studies
with purified recombinant mouse stromelysin-3 have
revealed weak stromelysin/proteoglycans activity.
With the exception of fibrillar collagenases, the
preferences of these enzymes for particular matrix sub-
strates in vivo is poorly defined. However, it is clear
that, collectively, matrix metalloproteinases are capa-
ble of degrading all of the components of the extracel-
lular matrix.
Recently, membrane-type metalloproteinases (MT-
MMP) were discovered [20]. MT-MMP is a
membrane-bound enzyme with recognized transmem-
brane domain. It appears to specifically activate proge-
latinase A [21]. Since the initial discovery, genes for
three other MT-MMPs have been identified and these
enzymes now constitute the fourth group of MMPs
[22]. MT-MMP is the only MMP so far identified that
is not a secreted product.
Many published reports have documented the pref-
erential localisation of proteases in adjuvant stromal
cells, rather than in invasive malignant cells. This sug-
gests that tumor cells can trigger the production of
proteases by the surrounding stromal cells [18, 23–
25]. This concept is supported by the partial charac-
terisation of a tumor cell-derived factor that stimulates
normal cells to produce collagenase, stromelysin and
gelatinase A [26].
Invasive cancer cells thus have the ability to
increase their proteolytic activity without increasing
their own production and secretion of proteases, and
they can concentrate and activate proteases in the peri-
cellular space. By producing a variety of proteases they
can also achieve optimal matrix degradation. This pro-
vides them with routes of escape against attempts to
control the production and secretion of proteases in
cancer cells. Because of this, inhibition of membrane-
bound activated proteases or of binding pro-enzyme to
membrane associated receptors may represent impor-
tant alternative ways to inhibit tumor cell proteolysis
[27, 28]. It may be important to target more than one
family of proteinases.
Matrix metalloproteinases in cancer
Normally, the degradative activity of MMPs is tightly
controlled both by the latency of the secreted enzymes
as well as by the presence of naturally occurring
inhibitors. The latter include general plasma proteinase
inhibitors such as a2-macroglobulin, as well as more
specific inhibitors such as the tissue inhibitors of metal-
loproteinases, TIMP-1 [29], TIMP-2 [30] and TIMP-3
[31]. However, in several diseases such as arthritis
[32], neurodegenerative disease such as multiple scle-
rosis [33] and cancer [34], there appears to be a local
and temporal imbalance between the levels of activated
enzymes and their inhibitors. This imbalance results in
a breakdown of the extracellular matrix. Several stud-
ies have shown that in cancer models the proportion of
active MMPs overwhelms the local inhibitory activity
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Table 2. Matrix metalloproteinase family
Matrix metalloproteinase MMP Preferred substrate
number
Class I
Interstitial collagenase 1 Fibrillar collagens, type I, II, III
Neutrophil (PMN) collagenase 8 Fibrillar collagens, type I, II, III
Collagenase-3 13 Fibrillar collagens, type I, II, III
Class II
Gelatinase A (72 kDa) 2 Collagen types IV, V, gelatin
Gelatinase B (92 kDa) 9 Collagen types IV, V, gelatin
Metalloelastase 12 Elastin
Class III
Stromelysin-1 3 Laminin, fibronectin, proteoglycans
Stromelysin-2 10 Laminin, fibronectin, proteoglycans
Matrilysin (pump) 7 Laminin, fibronectin, proteoglycans
Non-Classified
Stromelysin-3 11 1-antritrypsin?
Membrane-type MMP 14 Pro-gelatinase A
surrounding the tumor. This MMP activity facilitates
the direct expansion and local invasion of the primary
tumor, the movement of tumor cells across the vas-
cular basement membrane, and the local growth and
invasion of any secondary tumors. MMP activity also
contributes to the invasive ingrowth of new blood ves-
sels, a requisite for malignant tumor growth.
It is unlikely that every type of cancer uses MMPs to
break down matrix barriers, and other classes of pro-
teases, such as the urokinase-type plasminogen acti-
vator, are known to be expressed in high levels in
certain malignancies. One of the major challenges in
the development of matrix metalloproteinase inhibitors
(MMPIs) as anticancer agents is to identify which
cancers utilize MMPs and therefore might respond to
MMPI therapy. It is of utmost importance to realize that
very few human cancer cell lines and experimental in
vivo models reflect the MMP expression of the tumor
from which they were isolated. Therefore human tis-
sues taken at the time of primary surgery provide the
best insight into the role of MMPs in human cancer.
Collagenases
Fibrillar collagenase activity in epidermoid carcino-
mas of the oral cavity and larynx was found increased
compared to the activity in normal mucosa [35]. High
levels of fibrillar collagenase activity were also found
at the invading edge of gastric carcinomas [36], and in
colorectal cancer a correlation was detected between
collagenolytic activity and grade of histological differ-
entiation [37]. Further, interstitial collagenase in the
connective tissue stroma of colorectal carcinomas was
increased as compared with the staining in adenomas
and normal mucosa [38]. The cellular source of the col-
lagenase in these tumor tissues has long been a subject
of debate. Recent studies have localized mRNA encod-
ing interstitial collagenase to both invasive carcinoma
cells and stromal fibroblasts in epidermoid cancers of
the head and neck [39], and in 9 out of 22 lung can-
cers. mRNA encoding interstitial collagenase were not
detected in nine cases of prostate cancer [40].
Stromelysins
A high level of mRNA encoding for stromelysin-1 has
been detected in lung- and in head and neck cancer
[41], both in stromal and tumor cells. It was not found
in prostate [40], gastric or colorectal cancer [42]. In
contrast, high levels of PUMP-1 mRNA expression
were revealed in gastric and colorectal cancers [42]. In
the latter it was localized in tumor tissue or in adja-
cent stroma, with little or no expression in surrounding
normal tissue [18, 43]. High levels were also found in
prostate cancers, localized to the malignant and non-




High levels of activated gelatinase A were demonstrat-
ed in invasive cancer of the breast [44], while the ratio
of activated to latent gelatinase A was significantly
higher in malignant versus benign breast lesions and a
higher proportion of activated enzyme was related to
increasing tumor grade [45]. The expression of gelati-
nase A was correlated with the progression of colorec-
tal, gastric, and breast cancer [46], but failed to predict
relapse or survival in patients with node-negative breast
cancers [47]. Gelatinase A was also found to be higher
in invasive ovarian cancer than in benign cystadeno-
mas of the ovary, and was particularly intense around
micro-invasive cells or clusters [48]. It was significant-
ly elevated in sera of lung cancer patients as compared
to normal sera, and levels were also significantly higher
in patients with distant metastases versus those without
distant metastases [49]. In non-small cell lung cancer
and matched non-involved lung tissue there was also
a highly significant correlation between the level of
expression of gelatinase A and histopathological evi-
dence of tumor spread [50].
Gelatinase A was localized to the cells of the tumor-
associated stroma in both colorectal cancer [23] and
infiltrating squamous cell cancer of the skin [51]. In
the latter study, expression of the mRNA encoding
gelatinase B was localized to the squamous cancer cells
at the interface between tumor and stroma and was also
detected in a subpopulation of tissue macrophages.
Stromelysin-3
There have been several correlative studies in
breast cancer showing high levels of expression of
stromelysin-3 mRNA in tumor tissue or in adjacent
stroma, with little or no expression in surrounding nor-
mal tissue [18].
Only low levels of stromelysin-3 mRNA were
detected in colon, ovary, kidney and lung cancers.
More recently stromelysin-3 mRNA and protein have
been detected exclusively in the stromal cells sur-
rounding squamous cell cancers of the head and neck,
and these levels were significantly correlated to the
invasiveness of the cancer cells. In the samples, tran-
scripts for stromelysin-3 were localized exclusively in
the neoplastic cells, while those for interstitial col-
lagenase were found in both stromal and neoplastic
cells [3]. These results point to an important role for
stromelysin-3 in tumor progression and make it even
more important to understand the proteolytic function
of this metalloenzyme.
MT-MMP
MT-MMP, the membrane-bound enzyme with a recog-
nized transmembrane domain, appears to be a specific
activator of progelatinase A [21]. The expression of
MT-MMP by cancer cells would confer the ability to
activate gelatinase A produced locally by stromal cells
at the invasive tumor margins. In a study of gastric can-
cer, MT-MMP was expressed exclusively in the tumor
tissue and co-localised with activated gelatinase A in
invasive carcinoma cell nests [52].
Matrix metalloproteinase inhibition
Both native and synthetic inhibitors have been consid-
ered for therapeutic aims. The native inhibitors TIMP-
1 and TIMP-2, are potent broad spectrum inhibitors
(inhibiting collagenases, stromelysins and gelatinas-
es) and have been in development as therapeutic
agents since their identification and sequencing in 1985
(TIMP-1) [29] and 1989 (TIMP-2) [30]. However, the
therapeutic use of these proteins is likely to be limited
by their low oral bioavailability. Their size, 28 kDa
and 21 kDa respectively, may also limit tissue pene-
tration. Presently efforts are underway to characterize
the functional domains of the TIMP molecules [53,
54], hopefully yielding new synthetic or recombinant
approaches.
Synthetic matrix metalloproteinase inhibitors
(MMPIs) have been developed since the early 1980s.
The majority of these inhibitors are substituted pep-
tide derivatives, analogues of the cleavage site in the
collagen molecule with a metal-binding group in the
position of the cleaved peptide bond. the metal bind-
ing group, commonly a thiol, sulphydryl, carboxyl or
hydroxamate group, binds to the zinc atom in the activ-
ity site of the matrix metalloproteinase [55]. Poten-
cies have been reported in the low nanomolar range
and it has recently proved possible to design selective
inhibitors as well as broad spectrum agents. Selective
inhibitors are likely to be pursued with greater intensi-




It is of importance that in vitro studies with MMPIs
demonstrated absence of direct cytotoxicity. MMPIs
were first considered as potential antimetastatic agents.
This antimetastatic activity had been demonstrat-
ed in several experimental in vivo models of organ
colonisation by intravenously inoculated tumor cells.
Intraperitoneal administration of recombinant TIMP-
1 and TIMP-2 inhibited the colonisation of lungs
by both B16-F10 murine melanoma cells [56] and
ras-transfected rat embryo 4R cells [57]. Similar
results were obtained with the synthetic hydroxamate
MMPI SC44463 which yielded a > 90% inhibition of
lung colonisation by B16-F10 cells [58]. In addition,
intraperitoneal administration of the synthetic hydrox-
amate MMPI BB-94 (batimastat) was reported to sig-
nificantly inhibit lung colonisation and tumor growth
of B16-BL6 murine melanoma cells [59] and inhibit
by up to 80% both the number and median weights
of lung colonies by HOSP.1P rat mammary carcino-
ma cells [60]. This implied an effect on both seeding
efficiency and subsequent tumor growth.
However, these models only reflect the final stages
of hematogenous metastatic spread and do not pro-
vide information on the effects of these inhibitors on
lymphatic spread. In a spontaneous metastatic mod-
el, in which batimastat was given when subcutaneous
tumors were established until surgical removal or at
time of removal at day 70, lymphatic dissemination
was less susceptible to inhibition than hematogenous
spread. However, long-term treatment could prevent
the outgrowth of both lymphatic and lung micrometas-
tasis, allowing sustained tumor-free survival. These
results suggest, that MMPI treatment may directly sup-
press growth and development of lymphatic metasta-
sis, while the anti-angiogenic properties of these drugs
may relate to the inhibition of hematogenous metas-
tates [61].
Further studies have now provided a basis for the
development of MMPIs as both antitumor growth and
anti-angiogenic agents. In experiments with TIMP-
2 cDNA transfected rat embryo 4R cells it was
shown that production of TIMP-2 markedly reduced
tumor growth following subcutaneous implantation
[62]. Treatment with batimastat in a human ovarian
carcinoma xenograft ascites model in mice resulted in
important reduction of tumor burden, reduced tumor
growth and increased survival [63]. Transition of the
thick muscinous ascites to a solid avascular tumor was
associated with encapsulation of the clumps of tumor
cells by host stromal cells. This was proposed to be
caused by inhibition of intraperitoneal MMP activi-
ty with shifting of the balance from ECM breakdown
to formation of stromal connective tissue. The weak-
ly active diasteromer of BB-94 showed no antitumor
activity [63]. There was no evidence of vascularization
and there were signs of tumor cell necrosis.
Batimastat was further evaluated in several other
xenograft models. Inhibition of organ invasion was
reported in two human colorectal xenograft models
[64]. In a hepatic invasive model (C170HM2-cell line)
batimastat significantly reduced the number and size
of liver metastasis, while in the lung invasive mod-
el (AP5LV-cell line) a significant reduction of tumor
weight within the lung, but not in the number of nod-
ules was detected. In an orthotopic transplant model,
human colon-carcinoma xenografts were orthotopical-
ly implanted on the colon in mice. Intraperitoneal treat-
ment with batismastat not only reduced the number of
livermetastasis, but also caused a significant reduc-
tion in the median weight of the primary tumor and
incidence of local and regional invasion. This result-
ed in improved survival [65]. To evaluate an adjuvant
therapeutic potential, batimastat was administered to
mice after orthotopic human breast cancer xenografts
(MDA-MD-45) were resected [9]. Significant inhibi-
tion of locoregional tumor regrowth and reduction of
incidence, number and total volume of lung metasta-
sis was demonstrated. No effect was seen on cancer
cell viability in vitro and batimastat induced no major
change in individual MMP (72kDa type IV human col-
lagenase, stromelysin) or TIMP-2 gene expression, as
judged by steady-state mRNA levels.This suggests that
the inhibitory effect is solely due to MMP inhibition
[66].
A study using a human colorectal cancer
(C170HM2-cell line) ascites model in mice also
showed reduction of ascites formation and solid peri-
toneal tumor deposits [67]. However, another human
carcinoma ascites model showed conflicting results. In
this study, human breast cancer cells (MDA435/LCC6)
were used to generate malignant ascites in nude mice.
Treatment with batimastat resulted in major tumor cell
consolidation with less dispersed ascites cells, but with
evident residual tumor cell adhesions to peritoneal sur-
faces excluding significant reduction of overall tumor
burden. No increase in survival or significant suppres-
sion of ascites formation was found [68].
Of importance for potential clinical studies is the
observation that CT1746 (a gelatin selective synthet-
ic MMPI) in combination wit the cytotoxic agent
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cyclophosphamide was more effective than either agent
alone in the treatment of murine Lewis lung carcino-
ma, both for the delay in growth of the primary lesion
as well as for the number and size of lung metastates
[69].
Collectively these observations support the hypoth-
esis that MMPIs can act as antitumor agents by prevent-
ing remodelling of the extracellular matrix by tumor
cells. This action also appears to underlie the mech-
anism by which MMPIs can exert an anti-angiogenic
effect. In vitro studies have shown that both TIMP-1
and antisera to 72 kDa gelatinase can inhibit the invas-
tion of extracellular matrix by capillary endothelial
cells [1]. TIMP-1 has also been shown to inhibit tumor-
induced vascularisation of the rabbit cornea [70], pre-
sumably by blocking the remodelling of the extracel-
lular matrix that precedes new capillary growth. These
more recent studies broaden the range of action of
MMPIs.
We conclude that the reported preclinical studies
indicate that MMPIs not only have an antimetastatic
effect, but also inhibit steps in the whole metastatic
cascade such as invasive tumor growth and angiogene-
sis. Whether tumor-MMP production is predictive for
effect or site-specificity exist remains to be further elu-
cidated.
Clinical studies
Presently, few MMPIs have yet been evaluated in clin-
ical trials. Apart from specifically designed synthetic
MMPIs, there has also been recent clinical interest
in the use of tetracycline derivatives as antimetastatic
agents on the basis of their weak collagenase inhibitory
activity [71].
Batimastat was the first MMPI to be tested in cancer
patients. Because of the demonstrated low bioavailabil-
ity of batimastat oral administration was disregarded
and other ways of delivery routes were tested. Deduct-
ed from the earlier described ovarian cancer xenograft
model, batimastat was tested in patients with malignant
effusions. A phase I study of intraperiotoneal adminis-
trated batimastat in patients with symptomatic malig-
nant ascites was performed [72].Patients with any form
of malignancy who required paracentesis for symp-
tomatic relief were eligible. A single intraperitoneal
dose (150–1350 mg/m2) of batimastat, suspended in
5% dextrose, was given following drainage. The treat-
ment was generally well tolerated. Short lasting mild
abdominal pain associated with nausea and vomiting
was experienced by half of the patients. Treatment
resulted in postponement of paracentesis in several
patients. The intraperitoneal administration of a sin-
gle dose of 1000 mg/m2 resulted in high peak plasma
levels (Cmax 1000 ng/ml) and sustained plasma concen-
trations of 100–200 ng/ml after 4 weeks. The plasma
concentration time curve (AUC) was linear with dose.
The plasma half-life was 19 days. In a similar setting in
patients without ascites, batimastat was given at doses
of 600–1800 mg/m2, once every 4 weeks [73]. Max-
imal plasma levels were reached within 24–48 hours
following dosing, and levels > 160 ng/ml were main-
tained for 28 days. Systemic toxicities were minimal
to mild and similar to the ones reported above. Local
toxicities were of concern and included peritoneal irri-
tation, abdominal pain requiring narcotic analgesia,
vaso-vagal reactions and 1 case of bowel obstruction.
No significant changes were seen in the peripheral
blood activity of MMP-2 and -9. Four of nine patients
had stable disease lasting from 3–8 months. Although
a phase II study on i.p. batimastat was performed and
suggested some benefits in patients with ovarian can-
cer, further development of batimastat was halted for
this indication, in view of the local side effects of
administering the drug this way.
A similar approach was also taken in patients
with a symptomatic malignant pleural effusion [74].
Intrapleural batimastat was given at lower doses (15–
300 mg/m2) but nevertheless also resulted in a reduced
frequency of pleural aspirations. Side-effects were
mild and mainly consisted of some local discomfort.
Peak plasma levels achieved ranged from 12–170 times
the IC50 of MMP-2 and -9, 6–115 times the IC50 of
MMP-9 and 2–20 times that of MMP-3.
Objective tumor regression was not reported in
either study, which is in part (obviously) the resultant
of the chosen study design. These modes of admin-
istration are also limited by being impractical for a
widespread use. Since MMPIs in view of their mech-
anism of action require continuous exposure for effi-
cacy, present clinical development of MMPIs is again
focused on oral administration. This also relates to
an increased knowledge on the crystallographic struc-
ture of MMP-inhibitor complexes enabling a more
focused design of molecules with selectivity for spe-
cific MMPs, while it also allowed change in the
physicochemical properties of the inhibitor intended
to improve bioavailability through the oral route [75].
Marimastat was the second MMPI to be evaluat-
ed in cancer patients. Similar to batimastat and SC
44463 it binds to zinc in the MMP through hydrox-
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amic acid. A phase I study in healthy volunteers with
a single oral dose of 200 mg marimastat showed very
high peak plasma levels (Cmax > 750 ng/ml) and indi-
cated a terminal half life of approximately 9.5 hours.
Using a twice daily (bid) oral schedule of 50, 100 and
200 mg for 6 days, the drug was well tolerated and
50 mg bid was sufficient to achieve higher than MMP-
inhibitory IC50 levels [76]. Pharmacokinetic (PK) data
in patients with metastatic lung cancer using an interpa-
tient escalated (25–50 mg) bid oral schedule confirmed
inhibitory Cmax levels (180–580 ng/ml) with a terminal
half life of approximately 5 hours. No detailed data on
oral bioavailability nor PK data after prolonged admin-
istration were given [77].
The first dose finding phase I/II studies with mari-
mastat, depicted as ‘cancer antigen studies’ involved
patients with advanced ovarian, colorectal, pancreatic
or hormone-refractory prostate cancer that were treated
in similarly designed studies [78–84]. Inclusion criteria
included progressive disease defined as a tumor-marker
rise of  25% over the 4-week period prior to study
entry. Patients received an inter-patients escalated (5
mg o.d. to 75 mg bid) oral schedule of marimastat
for 4 weeks or until dose-limiting toxicity. Patients
who failed to demonstrate a continuing rise (> 25%)
of tumormarker levels were considered for long-term
treatment continuation.
Preliminary results were interesting. The respective
tumor markers CA 125, CEA, CA19.9 and PSA, were
all found to behave quite similarly under marimastat
therapy. In more than 50% of the patients treated for
4 weeks a diminished rise or an actual reduction of
marker level was detected.
A “meta-analysis” on 360 patients entered into
these studies showed marimastat to be maximally
effective at a dose of 10 mg bid and higher [85]. At
10 mg bid the mean 12 hour marimastat plasma level
of 81.9 ng/ml was 40 times higher than the IC50 of
marimastat for collagenase and gelatinase [86]. The
inhibitory effect on marker levels as described was
statistically significant and radiographic and clinical
assessment of patients on continued treatment indicat-
ed a possible stabilisation of disease, though without
objective tumor regression. The drug was generally
well tolerated and musculo-skeletal symptoms were
the principal side effect noted after prolonged treat-
ment. They consisted of pain and tenderness in mus-
cles, tendons and joints, predominantly in shoulders
and hands. The precise cause of these symptoms has
yet to be established, but they may be related to an
impairment of the normal process governing tissue
remodelling. It occurred in about 30% of patients by
five months of treatment at 10 mg bid and in 70% at 25
mg bid. The symptoms appeared to be dose-dependent,
resolved quickly after drug withdrawal and did not pre-
clude the possibility of continuation after a short drug
holiday.
Additional analyses of the survival data of those
patients continuing therapy beyond 4 weeks were
made. There appeared to be an inverse relationship
between the duration of survival and tumor marker
progression at time of study entry. This was suggested
by the authors as sufficient evidence to justify the use
of marker progression as a prognostic feature of clin-
ical outcome. In addition, a relationship was shown
between the extent of reduction in marker-progression
under marimastat treatment and the duration of sur-
vival with significant better survival outcome using a
10 mg bid schedule as compared to the suboptimal
doses of 5, 10 or 25 mg once a day. It should be noted
that these analyses were not defined prospectively, so
the data suggesting a beneficial effect from marimastat
on survival should be interpreted with caution.
Randomised comparative phase III trials of mari-
mastat are planned in pancreatic cancer, small cell lung
cancer, glioblastoma, gastric cancer and ovarian can-
cer. The study in pancratic cancer will compare dif-
ferent (5 mg, 10 mg and 25 mg) bid oral schedules of
marimastat to standard gemcitabine as first-line thera-
py.
Another synthetic MMPI that has entered clinical
phase I studies is CGS 27023 A, that shares the hydrox-
amic acid with marimastat as binding site to the zinc
atom in the MMP. Data of the clinical studies have not
been reported yet. Finally, reports on clinical studies
tetracycline related drug doxycycline are soon to be
expected.
In view of the major attention the clinical trials with
marimastat have received in the lay-press, it appears
worthwhile to discuss potentials, problems and practi-
calities of clinical trial design with MMPIs.
Clinical trial design
Clinical trials will need to be specifically designed to
optimally determine the toxicity and the therapeutic
potential of MMPIs, as they obtain their anti-tumor
effects through a unique mechanism of action.
To design such “tailored” studies, we will need to
find a balance between making optimal use of preclin-
ical information on one hand and the realization of the
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limited predictive value of this information for the clin-
ical situation on the other. Early attempts to draw up
specific guidelines for clinical trial design with MMPIs
have already been made [87]. Undoubtedly, recom-
mendations will be adjusted over time as more insight
in biological effects and experience in clinical studies
is gathered but it is useful to list the considerations to
be made in a rational fashion.
Preclinical studies showed that MMPIs can rather
be described as tumorostatic drugs as they inhibit-
ed invasive tumorgrowth, blocked neo-angiogenesis
and reduced metastatic spread without showing any
direct cytotoxicity. Translating these effects into a clin-
ical setting requires a new concept in cancer therapy.
Tumorostatic cancer therapy is an interesting alterna-
tive paradigm to be considered. The aim of such long-
term therapy would be to create a state of tumor ‘dor-
mancy’ by halting proliferation, and thus generating
disease stabilisation.
Consequently, the main difficulties in designing
clinical trials arise as no properly defined methods exist
to evaluate such therapy.
Conventional cytotoxic drugs are designed to max-
imally reduce tumor burden and treatment effect can
then be judged by well defined and standardised
response criteria. No major tumor mass reduction is
expected using MMPIs. Generally, early clinical trials
are conducted to obtain a toxicity profile, recommend
a therapeutic dose and establish clinical evidence of
efficacy, preferably in a short time span.
The expected required long-term treatment with
MMPIs requires minimal side-effects and an easy
administration schedule in order not to limit drug com-
pliance. The recommended therapeutic dose will thus
not be based on the maximally tolerated dose, but on
a dose with optimal biologic effect. We will have to
anticipate, and trials with batimastat and marimastat
have already confirmed this, that the toxicity profile
of MMPIs will markedly differ from those of conven-
tional cytotoxic drugs. Moreover, as mentioned sever-
al times, prolonged administration will be necessary.
Because of this, phase I trials should be designed in
such a way that subsequent cohorts of patients are not
put at risk because of the unavailability of long-term
results in the previous cohort. In addition it appears
worthwhile to introduce some type of pharmacody-
namic monitoring, since we are looking for the optimal
biologic dose rather than the maximally tolerable dose.
Present studies are all attempting to measure parame-
ters such as bone turnover products, capillary blood
flow (through doppler techniques) and angiogenesis
(through PET scanning), and zymographic assays to
determine plasma levels of MMPs. Obviously, in order
to relate to pharmacodynamic endpoints, pharmacoki-
netic data obtained by making use of sensitive assays,
will be crucial in all phase I and II studies. However, to
detect if the high pericellular MMP activity is actual-
ly inhibited, direct tissue determinations may be more
precise, yet are more difficult to acquire. Determin-
ing proenzymatic MMP serum levels may not be very
informative as MMPIs inhibit MMP activity and not
MMP secretion. These and other indirect parameters
of MMP activity are under investigation.
As discussed, regression of bulky cancer is not to be
expected by MMPIs. Such regression is commonly the
focus of clinical phase II studies. It seems inappropriate
to perform a wide variety of single agent phase II stud-
ies with MMPIs. As a single agent they might better be
studied initially in phase III studies in patients with a
very high likelihood of disease-recurrence, or disease
progression after initially induced disease response by
conventional cytotoxic agents. Development in clas-
sical adjuvant phase III studies would be too time-
consuming.
In addition, and in view of some preclinical data,
early combination studies of MMPIs with convention-
al cytotoxic drugs seem worthwhile pursuing. In this
case, randomized phase II studies comparing the com-
bination of the single agent cytotoxic drug would rapid-
ly provide crucial information on the potential additive
value of the MMPI. Tumor markers and other surro-
gate endpoints can helpful in guiding us through this
process but will never be sufficient to provide convinc-
ing evidence of efficacy.
Conclusion
Matrix metalloproteinases appear to be important
potential targets of antitumor therapies in view of their
increased levels in a wide variety of tumor types.
Because of their unique mechanism of action long-
term exposure may be a crucial factor, and both will
presumably also face us with new toxicology profiles.
Related to this, clinical trial design will have to be
different from the conventional one used for the devel-
opment of cytotoxic agents. Early clinical data on the
use of MMPI are interesting and support the continued
clinical development of this novel class of agents.
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